BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12190015)

  • 1. [Prenatal diagnosis for hereditary predisposition to mammary and ovarian carcinoma--defining a position].
    Cobben JM; Bröcker-Vriends AH; Leschot NJ
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1461-5. PubMed ID: 12190015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
    Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
    Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort.
    Fortuny D; Balmaña J; Graña B; Torres A; Ramón y Cajal T; Darder E; Gadea N; Velasco A; López C; Sanz J; Alonso C; Brunet J
    Hum Reprod; 2009 Apr; 24(4):1000-6. PubMed ID: 19112076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
    Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
    Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
    Wolff TA; Wilson JE
    Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutations of BRCA genes in hereditary breast and ovarian cancer.
    Radice P
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):9-12. PubMed ID: 12585647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical issues related to BRCA gene testing in orthodox Jewish women.
    Mor P; Oberle K
    Nurs Ethics; 2008 Jul; 15(4):512-22. PubMed ID: 18515440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct to confusion: lessons learned from marketing BRCA testing.
    Matloff E; Caplan A
    Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretest genetic counseling informs patients with BRCA mutation.
    Printz C
    Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
    [No Abstract]   [Full Text] [Related]  

  • 16. BRCA testing: ethics lessons for the new genetics.
    Sherwin S
    Clin Invest Med; 2004 Feb; 27(1):19-22. PubMed ID: 15061582
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal selection of individuals for BRCA mutation testing.
    Evans DG; Lalloo F; Eccles D
    J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
    [No Abstract]   [Full Text] [Related]  

  • 18. Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
    Matloff ET; Barnett RE; Bober SL
    Cancer J; 2009; 15(1):15-8. PubMed ID: 19197168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.